Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Meenakshi Patel

Geriatric Medicine Centerville, OH Medical Doctor

NPI 1568458362 CMS profile 298127

6611 Clyo Rd, Sutie E, Centerville, OH 45459

Open in the dashboard

General payments

$644,183

1,509 records reported · program years 2019–2025

Research payments

$93,262

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,248,750 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Meenakshi Patel of Centerville, OH is reported in the CMS Open Payments database as having received $644,183 across 1,509 general payments and $93,262 in research payments paid to them. Separately, studies naming them as principal investigator received $3,248,750 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43,798 124
2025 Research $1,538 7
2024 General $61,616 212
2023 General $112,737 247
2023 Research $1,994 1
2022 General $88,315 168
2022 Research $1,326 2
2021 General $99,299 194
2021 Research $72,107 3
2020 General $82,570 156
2019 General $155,850 408
2019 Research $16,297 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meenakshi Patel
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Meenakshi Patel were reported at $43,798. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Meenakshi Patel Geriatric Medicine median Middle half National median
2019 $155,850 $122 $40–$435 $163
2020 $82,570 $98 $25–$349 $114
2021 $99,299 $125 $34–$441 $132
2022 $88,315 $124 $36–$408 $149
2023 $112,737 $121 $41–$383 $160
2024 $61,616 $134 $41–$435 $164
2025 $43,798 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $165,368 341 payments
  2. Otsuka America Pharmaceutical, Inc. $129,654 181 payments
  3. Urovant Sciences Inc $50,732 62 payments
  4. Teva Pharmaceuticals USA, Inc. $50,176 71 payments
  5. Janssen Pharmaceuticals, Inc $44,632 90 payments
  6. AstraZeneca Pharmaceuticals LP $35,762 82 payments
  7. Sunovion Pharmaceuticals Inc. $27,941 49 payments
  8. Mylan Specialty L.P. $24,975 43 payments
  9. GlaxoSmithKline, LLC. $17,685 27 payments
  10. Sun Pharmaceutical Industries Inc. $17,459 41 payments
  11. Other $79,798 522 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $448,263 269 payments
  2. Consulting Fee $95,371 31 payments
  3. Travel and Lodging $63,885 299 payments
  4. Food and Beverage $22,262 892 payments
  5. Honoraria $13,122 8 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $938 1 payment
  7. Education $342 9 payments
Products named General payments · program years 2019–2025
  1. TRULICITY $151,003 246 payments
  2. REXULTI $129,701 180 payments
  3. GEMTESA $63,726 83 payments
  4. XARELTO $44,678 91 payments
  5. LOKELMA $35,204 56 payments
  6. YUPELRI $30,868 48 payments
  7. Austedo XR $26,442 38 payments
  8. AUSTEDO $23,636 31 payments
  9. EZALLOR SPRINKLE $17,212 29 payments
  10. Kerendia $16,973 114 payments
  11. Other $84,367 711 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $75,427 6 payments
  2. Genentech, Inc. $16,297 4 payments
  3. ACADIA Pharmaceuticals Inc $1,538 7 payments

Prescribing to Medicare patients

Part D · data year 2024 · 167 drugs

Part D claims

15,796

Median for Internal Medicine: 777

Drug cost

$1,603,189

Median for Internal Medicine: $73,373

Branded share of claims

24.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 650 $209,706
Xarelto Rivaroxaban Brand 454 $156,444
Trulicity Dulaglutide Brand 136 $145,765
Eliquis Apixaban Brand 406 $142,543
Entresto Sacubitril/Valsartan Brand 248 $105,507
Gemtesa Vibegron Brand 283 $88,319
Rebif Interferon Beta-1a/Albumin Brand 21 $81,333
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 85 $74,139
Prolia Denosumab Brand 28 $49,915
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 71 $38,206

The 10 drugs with the highest cost, of 167 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$148,994

Of which drugs: $9,478

Medicare patients

310

Average age 85

Services billed

2,006

214 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Heart failure 63%
Chronic kidney disease 61%
Depression 54%
Alzheimer's or dementia 48%
Diabetes 41%
Atrial fibrillation 40%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 51 52 $4,058
Pcv20 vaccine im 90677 Office 13 13 $3,779

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$33,156 19 —
YUPELRI
$10,920 20 —
Austedo XR
$8,149 — —
GEMTESA
$4,133 283 —
XARELTO
$3,500 454 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

1,526 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record